Wechselwirkungen · Viramune
Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 64
HOS-088310 · Präparat HOS-083615
ANTIVIRALS FOR CHRONIC HEPATITIS B AND C Adefovir Results of in vitro studies showed a Adefovir and Viramune may be weak antagonism of nevirapine by coadministered without dose adefovir (see section 5.1), this has adjustments. not been confirmed in clinical trials and reduced efficacy is not expected. Adefovir did not influence any of the common CYP isoforms known to be involved in human drug metabolism and is excreted renally. No clinically relevant drug-drug interaction is expected. Entecavir Entecavir is not a substrate, Entecavir and Viramune may be inducer or an inhibitor of coadministered without dose cytochrome P450 (CYP450) adjustments. enzymes. Due to the metabolic pathway of entecavir, no clinically relevant drug-drug interaction is expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): adefovir (HOS-088122) entecavir (HOS-088124)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage f1df31aae85f05c0ce7df9a3bd231e192da5c83812cad32934a7197875ecf9fc · Zeichen 18854–20001 im Abschnitt